To assess the efficacy of targeted therapy in NSCLC patients with HER2 alterations, we retrospectively enrolled patients with HER2 alterations who received anti-HER2 targeted therapy in our center. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.